Quoin Pharmaceuticals, Ltd.
QRX003
Netherton Syndrome
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for QRX003 in Netherton Syndrome are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“On March 25, 2026, Quoin provided a clinical and regulatory update from its constructive Type C meeting with the U.S. FDA for QRX003 in NS.”